Expression of fatty acid synthase depends on NAC1 and is associated with recurrent ovarian serous carcinomas

Journal of Oncology

Volumn , Issue , 2010, Pages

  Shih, Ie Ming ^a   Ueda, Stefanie M ^a   Yap, Kai Lee ^a   Davidson, Ben ^b,c   Tian, Yuan ^a   Murthy, Vivek ^a   Wang, Tian Li ^a   Visvanathan, Kala ^a   Kuhajda, Francis P ^a   Bristow, Robert E ^a   Zhang, Hui ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; C 93; CELL PROTEIN; FATTY ACID SYNTHASE; MUTANT PROTEIN; N130 PROTEIN; PROTEIN NAC1; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; ENZYME ASSAY; ENZYME INDUCTION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; OVARY CARCINOMA; OVERALL SURVIVAL; PROTEIN EXPRESSION; PROTEOMICS; RECURRENT CANCER; SEROSA; SURVIVAL TIME; TANDEM MASS SPECTROMETRY; TRANSCRIPTION REGULATION; TUMOR GROWTH; UPREGULATION;

EID: 77953527951     PISSN: 16878450     EISSN: 16878469     Source Type: Journal    
DOI: 10.1155/2010/285191     Document Type: Article

References (57)

1. Cho K. R., Shih I. M., Ovarian cancer Annual Review of Pathology: Mechanisms of Disease 2009 4 287 313
2. Kaye S. B., Reversal of drug resistance in ovarian cancer: where do we go from here? Journal of Clinical Oncology 2008 26 16 2616 2618
3. Nakayama K., Nakayama N., Davidson B., A BTB/POZ protein, NAC-1, is related to tumor recurrence and is essential for tumor growth and survival Proceedings of the National Academy of Sciences of the United States of America 2006 103 49 18739 18744
4. Abhiman S., Iyer L. M., Aravind L., BEN: a novel domain in chromatin factors and DNA viral proteins Bioinformatics 2008 24 4 458 461
5. Kim J., Chu J., Shen X., Wang J., Orkin S. H., An extended transcriptional network for pluripotency of embryonic stem cells Cell 2008 132 6 1049 1061
6. Wang J., Rao S., Chu J., A protein interaction network for pluripotency of embryonic stem cells Nature 2006 444 7117 364 368
7. Ma T., Wang Z., Guo Y., Pei D., The C-terminal pentapeptide of Nanog tryptophan repeat domain interacts with Nac1 and regulates stem cell proliferation but not pluripotency Journal of Biological Chemistry 2009 284 24 16071 16081
8. Stead M. A., Carr S. B., Wright S. C., Structure of the human Nac1 POZ domain Acta Crystallographica Section F 2009 65 5 445 449
9. Jinawath N., Vasoontara C., Yap K.-L., NAC-1, a potential stem cell pluripotency factor, contributes to paclitaxel resistance in ovarian cancer through inactivating Gadd45 pathway Oncogene 2009 28 18 1941 1948
10. Nakayama K., Nakayama N., Wang T.-L., Shih I.-M., NAC-1 controls cell growth and survival by repressing transcription of Gadd45GIP1, a candidate tumor suppressor Cancer Research 2007 67 17 8058 8064
11. Liu H., Sadygov R. G., Yates J. R. III, A model for random sampling and estimation of relative protein abundance in shotgun proteomics Analytical Chemistry 2004 76 14 4193 4201
12. Pohl G., Ho C.-L., Kurman R. J., Bristow R., Wang T.-L., Shih I.-M., Inactivation of the mitogen-activated protein kinase pathway as a potential target-based therapy in ovarian serous tumors with KRAS or BRAF mutations Cancer Research 2005 65 5 1994 2000
13. Han D. K., Eng J., Zhou H., Aebersold R., Quantitative profiling of differentiation-induced microsomal proteins using isotope-coded affinity tags and mass spectrometry Nature Biotechnology 2001 19 10 946 951
14. Keller A., Nesvizhskii A. I., Kolker E., Aebersold R., Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search Analytical Chemistry 2002 74 20 5383 5392
15. Davidson B., Berner A., Trope' C. G., Wang T.-L., Shih I.-M., Expression and clinical role of the bric-a-brac tramtrack broad complex/poxvirus and zinc protein NAC-1 in ovarian carcinoma effusions Human Pathology 2007 38 7 1030 1036
16. Kuhajda F. P., Fatty acid synthase and cancer: new application of an old pathway Cancer Research 2006 66 12 5977 5980
17. Kuhajda F. P., Jenner K., Wood F. D., Fatty acid synthesis: a potential selective target for antineoplastic therapy Proceedings of the National Academy of Sciences of the United States of America 1994 91 14 6379 6383
18. Gansler T. S., Hardman W. III, Hunt D. A., Schaffel S., Hennigar R. A., Increased expression of fatty acid synthase (OA-519) in ovarian neoplasms predicts shorter survival Human Pathology 1997 28 6 686 692
19. Epstein J. I., Carmichael M., Partin A. W., OA-519 (fatty acid synthase) as an independent predictor of pathologic stage in adenocarcinoma of the prostate Urology 1995 45 1 81 86
20. Alo' P. L., Visca P., Marci A., Mangoni A., Botti C., Di Tondo U., Expression of fatty acid synthase (FAS) as a predictor of recurrence in stage I breast carcinoma patients Cancer 1996 77 3 474 482
21. Rashid A., Pizer E. S., Moga M., Elevated expression of fatty acid synthase and fatty acid synthetic activity in colorectal neoplasia American Journal of Pathology 1997 150 1 201 208
22. Milgraum L. Z., Witters L. A., Pasternack G. R., Kuhajda F. P., Enzymes of the fatty acid synthesis pathway are highly expressed in in situ breast carcinoma Clinical Cancer Research 1997 3 11 2115 2120
23. Pizer E. S., Wood F. D., Heine H. S., Romantsev F. E., Pasternack G. R., Kuhajda F. P., Inhibition of fatty acid synthesis delays disease progression in a xenograft model of ovarian cancer Cancer Research 1996 56 6 1189 1193
24. Orita H., Coulter J., Tully E., Kuhajda F. P., Gabrielson E., Inhibiting fatty acid synthase for chemoprevention of chemically induced lung tumors Clinical Cancer Research 2008 14 8 2458 2464
25. Jensen V., Ladekarl M., Holm-Nielsen P., Melsen F., Soerensen F. B., The prognostic value of oncogenic antigen 519 (OA-519) expression and proliferative activity detected by antibody MIB-1 in node-negative breast cancer Journal of Pathology 1995 176 4 343 352
26. Shurbaji M. S., Kalbfleisch J. H., Thurmond T. S., Immunohistochemical detection of a fatty acid synthase (OA-519) as a predictor of progression of prostate cancer Human Pathology 1996 27 9 917 921
27. Menendez J. A., Lupu R., Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis Nature Reviews Cancer 2007 7 10 763 777
28. Zhou W., Wan F. H., Landree L. E., Fatty acid synthase inhibition activates AMP-activated protein kinase in SKOV3 human ovarian cancer cells Cancer Research 2007 67 7 2964 2971
29. Di Vizio D., Sotgia F., Williams T. M., Caveolin-1 is required for the upregulation of fatty acid synthase (FASN), a tumor promoter, during prostate cancer progression Cancer Biology and Therapy 2007 6 8 1263 1268
30. Lee M.-Y., Moon J.-S., Park S. W., Koh Y.-K., Ahn Y.-H., Kim K.-S., KLF5 enhances SREBP-1 action in androgen-dependent induction of fatty acid synthase in prostate cancer cells Biochemical Journal 2009 417 1 313 322
31. Korutla L., Wang P., Jackson T. G., Mackler S. A., NAC1, a POZ/BTB protein that functions as a corepressor Neurochemistry International 2009 54 3-4 245 252
32. Korutla L., Degnan R., Wang P., Mackler S. A., NAC1, a cocaine-regulated POZ/BTB protein interacts with CoREST Journal of Neurochemistry 2007 101 3 611 618
33. Korutla L., Wang P. J., Mackler S. A., The POZ/BTB protein NAC1 interacts with two different histone deacetylases in neuronal-like cultures Journal of Neurochemistry 2005 94 3 786 793
34. Liu H., Liu Y., Zhang J.-T., A new mechanism of drug resistance in breast cancer cells: fatty acid synthase overexpression-mediated palmitate overproduction Molecular Cancer Therapeutics 2008 7 2 263 270
35. Vazquez-Martin A., Ropero S., Brunet J., Colomer R., Menendez J. A., Inhibition of fatty acid synthase (FASN) synergistically enhances the efficacy of 5-fluorouracil in breast carcinoma cells Oncology Reports 2007 18 4 973 980
36. Song J., Shih I.-M., Salani R., Chan D. W., Zhang Z., Annexin XI is associated with cisplatin resistance and related to tumor recurrence in ovarian cancer patients Clinical Cancer Research 2007 13 22 6842 6849
37. Shih I.-M., Sheu J. J.-C., Santillan A., Amplification of a chromatin remodeling gene, Rsf-1/HBXAP, in ovarian carcinoma Proceedings of the National Academy of Sciences of the United States of America 2005 102 39 14004 14009
38. Sorrentino A., Liu C.-G., Addario A., Peschle C., Scambia G., Ferlini C., Role of microRNAs in drug-resistant ovarian cancer cells Gynecologic Oncology 2008 111 3 478 486
39. Gupta D., Venkatesh M., Wang H., Expanding the roles for pregnane X receptor in cancer: proliferation and drug resistance in ovarian cancer Clinical Cancer Research 2008 14 17 5332 5340
40. Ishibashi M., Nakayama K., Yeasmin S., A BTB/POZ gene, NAC-1, a tumor recurrence-associated gene, as a potential target fortaxol resistance in ovarian cancer Clinical Cancer Research 2008 14 10 3149 3155
41. Wang J., Zhou J.-Y., Wu G. S., ERK-dependent MKP-1-mediated cisplatin resistance in human ovarian cancer cells Cancer Research 2007 67 24 11933 11941
42. Kuhajda F. P., Landree L. E., Ronnett G. V., The connections between C75 and obesity drug-target pathways Trends in Pharmacological Sciences 2005 26 11 541 544
43. Pizer E. S., Chrest F. J., DiGiuseppe J. A., Han W. F., Pharmacological inhibitors of mammalian fatty acid synthase suppress DNA replication and induce apoptosis in tumor cell lines Cancer Research 1998 58 20 4611 4615
44. Wang H. Q., Altomare D. A., Skele K. L., Positive feedback regulation between AKT activation and fatty acid synthase expression in ovarian carcinoma cells Oncogene 2005 24 22 3574 3582
45. Grunt T. W., Wagner R., Grusch M., Interaction between fatty acid synthase- and ErbB-systems in ovarian cancer cells Biochemical and Biophysical Research Communications 2009 385 3 454 459
46. Uddin S., Siraj A. K., Al-Rasheed M., Fatty acid synthase and AKT pathway signaling in a subset of papillary thyroid cancers Journal of Clinical Endocrinology and Metabolism 2008 93 10 4088 4097
47. Cheng J. Q., Godwin A. K., Bellacosa A., AKT2, a putative oncogene encoding a member of a subfamily of protein- serine/threonine kinases, is amplified in human ovarian carcinomas Proceedings of the National Academy of Sciences of the United States of America 1992 89 19 9267 9271
48. Li J.-N., Gorospe M., Chrest F. J., Pharmacological inhibition of fatty acid synthase activity produces both cytostatic and cytotoxic effects modulated by p53 Cancer Research 2001 61 4 1493 1499
49. Lu X., Errington J., Curtin N. J., Lunec J., Newell D. R., The impact of p53 status on cellular sensitivity to antifolate drugs Clinical Cancer Research 2001 7 7 2114 2123
50. O'Connor P. M., Jackman J., Bae I., Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents Cancer Research 1997 57 19 4285 4300
51. Salani R., Kurman R. J., Giuntoli R. II, Assessment of TP53 mutation using purified tissue samples of ovarian serous carcinomas reveals a higher mutation rate than previously reported and does not correlate with drug resistance International Journal of Gynecological Cancer 2008 18 3 487 491
52. Rossi S., Graner E., Febbo P., Fatty acid synthase expression defines distinct molecular signatures in prostate cancer Molecular Cancer Research 2003 1 10 707 715
53. Fiorentino M., Zadra G., Palescandolo E., Overexpression of fatty acid synthase is associated with palmitoylation of Wnt1 and cytoplasmic stabilization of -catenin in prostate cancer Laboratory Investigation 2008 88 12 1340 1348
54. Coleman D. T., Bigelow R., Cardelli J. A., Inhibition of fatty acid synthase by luteolin post-transcriptionally down-regulates c-Met expression independent of proteosomal/lysosomal degradation Molecular Cancer Therapeutics 2009 8 1 214 224
55. Little J. L., Wheeler F. B., Koumenis C., Kridel S. J., Disruption of crosstalk between the fatty acid synthesis and proteasome pathways enhances unfolded protein response signaling and cell death Molecular Cancer Therapeutics 2008 7 12 3816 3824
56. Furuta E., Pai S. K., Zhan R., Fatty acid synthase gene is up-regulated by hypoxia via activation of Akt and sterol regulatory element binding protein-1 Cancer Research 2008 68 4 1003 1011
57. Harris A. L., Hypoxiaa key regulatory factor in tumour growth Nature Reviews Cancer 2002 2 1 38 47